IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
T cell-based immunotherapy has significantly improved treatment options for many malignancies. However, despite these and other therapeutic improvements over the last decades, gastrointestinal cancers, in particular pancreatic, hepatic and gastric cancer, are still characterized by high relapse rate...
Main Authors: | Martina S. Lutz, Latifa Zekri, Laura Weßling, Susanne Berchtold, Jonas S. Heitmann, Ulrich M. Lauer, Gundram Jung, Helmut R. Salih |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1163136/full |
Similar Items
-
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3)
by: Susanne Jung, et al.
Published: (2024-02-01) -
1366 B7-H3xCD3 bispecific antibody as novel treatment option in HER2-negative breast cancer
by: Ilona Hagelstein, et al.
Published: (2023-11-01) -
Bispecific Antibodies in Prostate Cancer Therapy: Current Status and Perspectives
by: Jonas S. Heitmann, et al.
Published: (2021-02-01) -
An Fc-Optimized CD133 Antibody for Induction of Natural Killer Cell Reactivity Against Colorectal Cancer
by: Bastian J. Schmied, et al.
Published: (2019-06-01) -
CD18 Antibody Application Blocks Unwanted Off-Target T Cell Activation Caused by Bispecific Antibodies
by: Joseph Kauer, et al.
Published: (2021-09-01)